New herpes vaccine passes first safety check in small trial
NCT ID NCT01915212
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 31 times
Summary
This early-stage trial tested whether a new vaccine called HSV529 is safe for people. The vaccine aims to prevent genital herpes caused by the herpes simplex virus type 2. A total of 69 healthy adults aged 18 to 40 received either the vaccine or a placebo shot. Researchers monitored them for side effects and immune responses over one year.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HSV529 vaccine
What this could lead to
If successful, this could pave the way for a vaccine to prevent genital herpes infections.
What could go wrong
This is an early Phase 1 safety trial with only 69 people, so it cannot prove the vaccine works. Larger studies are needed to test effectiveness.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.